ProBioGen AG, a service and technology provider for complex therapeutic antibodies and glycoproteins, has entered a license agreement with Bayer AG for the  GlymaxX Technology. Under the agreement, Bayer will leverage the technology to further increase the potency of an undisclosed antibody candidate for oncological indications.

ProBioGen’s antibody-dependent cellular cytotoxicity (ADCC) enhancing technology GlymaxX will be applied during cell line development.

“We are glad to add Bayer to our list of licensees”, said ProBioGen’s Chief Executive Officer Dr. Wieland Wolf. “The GlymaxX® technology is clinically proven and is a very flexible technology which is liked by all cell lines.”